16 completed, 7 terminated, 7 unknown, 4 withdrawn. 38 Phase 3, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 38 | Completed 16, Terminated 7, Unknown 7, Withdrawn 4, Recruiting 2, Not yet recruiting 1, Suspended 1 |
| Phase 2 | 14 | Completed 7, Unknown 4, Recruiting 1, Terminated 1, Withdrawn 1 |
Follow COVID: new trials by email Literature Review of COVID trials Research Report on COVID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 RESP301 - Pulmonary Complications in Surgical Patients, COVID | Phase 3 | Suspended | University of Birmingham | 6400 | 2022-05-16 | 2025-02-20 |
| Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 3 | Withdrawn | APR Applied Pharma Research s.a. | 2021-12-15 | 2026-05-14 | |
| Outpatient Treatment With Anti-Coronavirus Immunoglobulin Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo - COVID, SARS-CoV2 Infection | Phase 3 | Terminated | University of Minnesota | 741 | 2021-08-06 | 2026-08-13 |
| Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease Maintenance or reduction of immunosuppression - COVID, Kidney Transplant; Complications | Phase 2 / Phase 3 | Withdrawn | Brigham and Women's Hospital | 2021-05-03 | 2022-05-04 | |
| Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 2 / Phase 3 | Terminated | APR Applied Pharma Research s.a. | 144 | 2021-02-15 | 2023-02-03 |
| Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation Propranolol Hydrochloride - Mechanical Ventilation, Sedation | Phase 3 | Completed | Ottawa Hospital Research Institute | 72 | 2021-01-08 | 2022-12-05 |
| Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo, Remdesivir - COVID, COVID-19 | Phase 3 | Completed | University of Minnesota | 593 | 2020-10-08 | 2022-04-04 |
| New Antiviral Drugs for Treatment of COVID-19 Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days : - COVID, Drug Effect | Phase 3 | Unknown | Mansoura University | 100 | 2020-10-01 | 2020-09-03 |
| P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 P2Et (Caesalpinia spinosa extract), Placebo - COVID, Coronavirus Infection | Phase 2 / Phase 3 | Unknown | Hospital Universitario San Ignacio | 100 | 2020-09-30 | 2021-08-10 |
| Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease NP-120 (Ifenprodil) - COVID | Phase 2 / Phase 3 | Completed | Algernon Pharmaceuticals | 168 | 2020-08-05 | 2021-12-03 |
| Sofosbuvir in Treatment of COVID 19 sofosbuvir, Sofosbuvir ledipsavir, Daclatasvir - COVID | Phase 2 / Phase 3 | Unknown | Tanta University | 60 | 2020-08-01 | 2020-12-08 |
| Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation mavrilimumab, Placebo - COVID | Phase 2 / Phase 3 | Completed | Kiniksa Pharmaceuticals International, plc | 814 | 2020-07-28 | 2025-01-22 |
| A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic Therapeutic anticoagulation - COVID, Coronavirus Infection | Phase 3 | Completed | University of Sao Paulo General Hospital | 465 | 2020-07-04 | 2021-10-26 |
| BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots BCG vaccine (Freeze-dried) - COVID | Phase 3 | Completed | Tuberculosis Research Centre, India | 2175 | 2020-07-01 | 2022-07-08 |
| Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID19) in Non-intubated Patients Systemic indirect endovenous ozone therapy - COVID | Phase 3 | Unknown | Javier Hidalgo Tallón | 50 | 2020-07-01 | 2020-06-23 |
| Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19 Chloroquine or hydroxychloroquine, zinc - COVID | Phase 3 | Completed | Tanta University | 191 | 2020-06-23 | 2022-04-01 |
| The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment Ivermectin - COVID | Phase 2 / Phase 3 | Recruiting | Tanta University | 300 | 2020-06-16 | 2021-03-10 |
| Remdesivir Efficacy in Coronavirus Disease Remdesivir, Standard of care treatment - COVID | Phase 2 / Phase 3 | Completed | Tanta University | 200 | 2020-06-16 | 2021-08-02 |
| Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 Convalescent Plasma, Standard of Care - COVID | Phase 3 | Completed | Institute of Liver and Biliary Sciences, India | 400 | 2020-06-14 | 2021-10-14 |
| High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy Enoxaparin - COVID, Pneumonia, Viral | Phase 3 | Unknown | Azienda Ospedaliero-Universitaria di Modena | 300 | 2020-06-01 | 2020-05-29 |
Showing 20 of 38. Sign in to see all of them.
COVID-19 (12) · Coronavirus Infections (7) · Pneumonia (4) · Respiratory Distress Syndrome (4) · Pneumonia, Viral (3) · Severe Acute Respiratory Syndrome (3) · Acute Lung Injury (2) · Cytokine Release Syndrome (2) · Dyspnea (2) · Hemostatic Disorders (2) · Thrombosis (2) · Communicable Diseases (1) · Critical Illness (1) · Venous Thromboembolism (1)
Respiratory Tract Diseases (18) · Lung Diseases (17) · Infections (16) · Coronaviridae Infections (15) · Nidovirales Infections (15) · RNA Virus Infections (15) · Virus Diseases (15) · Respiratory Tract Infections (14) · Pneumonia, Viral (10) · Pneumonia (9) · Coronavirus Infections (8) · Pathological Conditions, Signs and Symptoms (6) · Cardiovascular Diseases (4) · Pathologic Processes (4) · Respiration Disorders (4)
Hydroxychloroquine (5) · Ivermectin (5) · Chloroquine (4) · Enoxaparin (3) · Standard of Care (3) · HIV hyperimmune globulin (2) · Heparin (2) · Lopinavir (2) · Ritonavir (2) · aviptadil (2) · remdesivir (2) · Azithromycin (1) · BCG Vaccine (1) · BID protein, human (1) · Captopril (1)
Tanta University (8) · APR Applied Pharma Research s.a. (2) · Brigham and Women's Hospital (2) · University of Minnesota (2) · Zagazig University (2) · Algernon Pharmaceuticals (1) · Azienda Ospedaliero-Universitaria di Modena (1) · Barcelona Institute for Global Health (1) · Beneficência Portuguesa de São Paulo (1) · Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva (1) · Fabrizio Cantini (1) · Fondation Hôpital Saint-Joseph (1) · Hospital Universitario San Ignacio (1) · Icahn School of Medicine at Mount Sinai (1) · Institute of Liver and Biliary Sciences, India (1)
Egypt (11) · United States (8) · Brazil (4) · Spain (4) · Denmark (3) · Australia (2) · Colombia (2) · Greece (2) · India (2) · Italy (2) · Nigeria (2) · Peru (2) · United Kingdom (2) · Argentina (1) · Canada (1)
Jonathan C Javitt, MD, MPH (2) · Sherief Abd-Elsalam, ass. prof. (2) · Alex C Spyropoulos, MD (1) · Anant Mohan (1) · Andri MT Lubis, MD, PhD (1) · Aneel Bhangu (1) · Annetine C Gelijns, PhD (1) · Asha Keetharam (1) · Cavan Reilly, PhD (1) · Clara Clausen, MD (1) · Elnara M Negri, MD, PhD (1) · Hassan Rahhal, MD (1) · Hemant Deshmukh (1)
PMID 33502773, PMID 35244208, PMID 36216961, PMID 16287208, PMID 25108173, PMID 30531947, PMID 31978945, PMID 32251768, PMID 32407672, PMID 32616063, PMID 33247380, PMID 33472855, PMID 33492523, PMID 33591017, PMID 33715160, PMID 33907251, PMID 34268513, PMID 34473343, PMID 34617959, PMID 35093205, PMID 35387813, PMID 36160152, PMID 36180450, PMID 36695483, PMID 37591523, PMID 37794281, PMID 38098221, PMID 38767196, PMID 39982178